A multiplex, prime editing framework for identifying drug resistance variants at scale
Preprint
Abstract
CRISPR-based genome editing has revolutionized functional genomics, enabling screens in which thousands of perturbations of either gene expression or primary genome sequence can be competitively assayed in single experiments. However, for libraries of specific mutations, a challenge of CRISPR-based screening methods such as saturation genome editing is that only one region ( e.g. one exon) can be studied per experiment. Here we describe prime-SGE (“prime saturation genome editing”), a new framework based on prime editing, in which libraries of specific mutations can be installed into genes throughout the genome and functionally assessed in a single, multiplex experiment. Prime-SGE is based on quantifying the abundance of prime editing guide RNAs (pegRNAs) in the context of a functional selection, rather than quantifying the mutations themselves. We apply prime-SGE to assay thousands of single nucleotide changes in eight oncogenes for their ability to confer drug resistance to three EGFR tyrosine kinase inhibitors. Although currently restricted to positive selection screens by the limited efficiency of prime editing, our strategy opens the door to the possibility of functionally assaying vast numbers of precise mutations at locations throughout the genome.Keywords
This publication has 52 references indexed in Scilit:
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Saturation editing of genomic regions by multiplex homology-directed repairNature, 2014
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domainPigment Cell & Melanoma Research, 2013
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?Journal of Clinical Oncology, 2013
- Converting Cancer Therapies into Cures: Lessons from Infectious DiseasesCell, 2012
- Epidermal growth factor receptor mutation in gastric cancerPathology, 2011
- Clinical implications of novel activating EGFR mutations in malignant peritoneal mesotheliomaWorld Journal of Surgical Oncology, 2010
- EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsilEuropean Journal of Cancer, 2007